Corticosteroid Exposure Affects Bone Health in Asthma Patients
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures
Allergic Disorders
Assessing the Effect of 2019 GINA Classification Changes in Patients With Asthma
Researchers sought to characterize the effect of the changes in the GINA 2019 recommendations in a real-world patient setting.
Dupilumab Associated With Reduced Severe Outpatient Asthma Exacerbation Rates
In patients with type 2 asthma, dupilumab was associated with significantly lower annualized outpatient asthma exacerbation rates and lower total number of days using systemic corticosteroids.
Early Introduction of Gluten Linked to Decline in Celiac Disease
Introduction of gluten from age 4 months linked to reduced prevalence of celiac disease.
OTC Medicines Containing “Clean” Inactive Ingredients Launched
Genexa has launched 4 over-the-counter (OTC) medicines that contain no artificial ingredients.
Dupilumab Gets Breakthrough Therapy Status for Eosinophilic Esophagitis
The designation was based on results from Part A of a double-blind, placebo-controlled, pivotal phase 3 trial.
FDA to Review Omalizumab Prefilled Syringe for Self-Administration
The FDA is expected to make a decision by the first quarter of 2021.
Epinephrine Sublingual Film Gets Fast Track Status for Anaphylaxis
AQST-108 is a sublingual film that delivers systemic epinephrine utilizing the Company’s proprietary technology.
Adolescents Who Use E-Cigarettes, Marijuana May Have Higher Odds of Lifetime Asthma
Electronic cigarette use is associated with lifetime asthma in US adolescents, and may become more damaging when combined with marijuana or cigarette smoking.
MPR Weekly Dose Podcast Episode 46
This week there’s more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.
